Search

In the 20 patients with prostatic carcinoma (PC) and the 18 with benign prostatic hyperplasia (BPH) the level of tissue type plasminogen activator (t-PA:Ag) was examined. As a compared group consisted of 24 healthy volunteers. In the urine of examined patients with PC and BPH and control the t-PA:Ag was absent or present only in trace amounts. We concluded that the t-PA:Ag in the urine of patients with PC can not be as a marker in the diagnosis of prostatic diseases especially in the prostatic carcinoma.

The activity of alpha 2-macroglobulin in the blood of the patients with prostatic carcinoma (PC) and benign prostatic hyperplasia (BPH) was examined. It was shown an decrease of alpha 2-macroglobulin in patients with prostatic carcinoma in comparison with control group consisted of the patients with benign prostatic hyperplasia. The low activity of alpha 2-macroglobulin in the blood od the patients with PC can be a symptom of an increase risk of haemorrhagic complications.

In 30 patients with prostatic carcinoma a higher of t-PA, a low of PAI-1, alpha 2-antiplasmin and plasminogen activity with increased fibrin degradation products (FDP) level and a short euglobulin lysis time (ELT) were observed. Following surgery a further increased of fibrinolytic activity occurred. The activity of t-PA and PAI-1 were higher than before operation. Apart from that we observed a decreased of plasminogen and alpha 2-AP with further increased level of FDP. On 5-th day the values of examined parameters were similar as before the operation.

We reported on a 74 year old patients with local advanced prostatic carcinoma. Following prostatic surgery an increased bleeding tendency was observed. The patients showed clinical and laboratory evidence for consumption coagulopathy with hyperfibrinolysis. The laboratory data were: marked decrease of AT III, Protein C, increase of thrombin/AT III complex level, fibrin degradation products (FDP) and antigen of t-PA. The treatment was ended successful.

In the blood of 20 patients with prostatic carcinoma the level of alpha 2-antiplasmin and plasminogen were examined. The control group consisted of 20 patients with benign prostatic hyperplasia. The low activity of alpha 2-antiplasmin in the blood of the patients with prostatic carcinoma was observed. The level of plasminogen was similar in both groups and it was in the low part of laboratory normal range. We concluded that the low levels of plasminogen and alpha 2-antiplasmin were a result of their consumption during activation of fibrinolysis process. The measurement of the alpha 2-antiplasmin and plasminogen can be useful to predict a risk of bleeding complications in the patients with prostatic carcinoma and benign prostatic hyperplasia.

The activity of alpha 1-antitrypsin in the blood of the patients with prostatic carcinoma and benign prostatic hyperplasia before and after the operation was examined. It was observed an increase of alpha 1-antitrypsin in the blood of patients with prostatic carcinoma and benign prostatic hyperplasia after the operation. In the blood patients of control group an increase of alpha 1-antitrypsin was observed too. The activity of alpha 1-antitrypsin in prostatic carcinoma was the highest during the whole observation period. The similar increase of the activity of alpha 1-antitrypsin after the operation in the blood of all groups of patients is connected with inflammatory reaction. The highest activity of alpha 1-antitrypsin in the blood of patients with prostatic carcinoma is the proof that the malignant neoplasm is associated with much more inflammatory reaction and the further hormonal treatment can be connected with a risk of thromboembolic complications.

The activity of alpha 1-antitrypsin in patients with prostatic carcinoma and benign prostatic hyperplasia was examined. The activity of alpha 1-antitrypsin was higher in patients with prostatic carcinoma. The higher activity of alpha 1-antitrypsin is good prognostic sign for patients with prostatic carcinoma because it is born of large defense possibilities in these patients against the disease.

The activity of Protein C in the blood of the patients with prostatic carcinoma and benign prostatic hyperplasia was examined. It was observed a slightly decrease of activity of protein C in the blood the patients with prostatic carcinoma. The observation of the activity of Protein C is useful because it allow to differentiate from patients with prostatic carcinoma a group of high risk of haemorrhagic complications. The activity of Protein C may be a prognostic factor of a progress of a prostatic carcinoma.